Tech Company Financing Transactions
Biorelate Funding Round
Maven Capital, YFM Equity Partners and private investors participated in a $8 million Series A funding round for Biorelate. The round closed on 11/29/2022.
Transaction Overview
Company Name
Announced On
11/29/2022
Transaction Type
Venture Equity
Amount
$8,000,000
Round
Series A
Investors
Maven Capital (Lead Investor)
YFM Equity Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds to expand its product, sales and marketing departments, and establish operations in the US.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Unit 9 Williams House Manchester Science Park Lloyd St N
Manchester, M15 6SE
UK
Manchester, M15 6SE
UK
Phone
Undisclosed
Website
Email Address
Overview
Biorelate was founded in 2014 from cutting-edge scientific research into how biomedical curation can utilise existing dark knowledge to accelerate future drug discovery. Staying true to our roots, we have always believed that a better understanding of today's science can bring forward the next generation of life-saving therapeutics being developed by world leading researchers.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kevin Cox
Chief Executive Officer
Daniel Jamieson
VP - Client Services
Stephen Newhouse
VP - Engineering
Darren Hoyland
VP - Sales
Mark Hughes
Browse more venture capital transactions:
Prev: 11/29/2022: Propagate venture capital transaction
Next: 11/29/2022: Jurata Thin Film venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from company press releases and news coverage. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs